Sofosbuvir, a Significant Paradigm Change in HCV Treatment

Thomas McQuaid*1, Carolyn Savini2 and Star Seyediakhzemi3

1Medical Affairs, Gilead Sciences, Norwalk, CT, USA; 2Medical Affairs, Gilead Sciences, Dallas, TX, USA; 3Medical Affairs, Gilead Sciences, Foster City, CA, USA

Abstract

Nucleotide compounds like sofosbuvir, acyclovir, and tenofovir have proven to be amongst the most potent orally available antiviral treatments. These drugs exhibit high efficacy and a wide therapeutic index, with demonstrated utility in a number of chronic viral infections. The approval of Sovaldi™, brand name for sofosbuvir, by the U.S. Food and Drug Administration heralded improvements in chronic hepatitis C virus (HCV) treatment. Sofosbuvir was originally discovered by Pharmasset Corporation and named PSI-7977. It was subsequently acquired and advanced through phase 3 development by Gilead Sciences, Inc. In Sofosbuvir both a unique pharmacology and a high specificity for the HCV ribonucleic acid polymerase are present in a molecule that is well tolerated and highly efficacious. Phase 2 and 3 clinical trials have consistently demonstrated durable and high rates of sustained virologic response (SVR), curing patients in excess of 80% in all genotypes and >90% in treatment-naive subjects being administered combination therapy with other agents. Harvoni™ is the combination of sofosbuvir and the NS5A inhibitor ledipasvir in a fixed-dose oral tablet, and it has demonstrated high SVR rates in patients infected with HCV genotype 1, without the need for exogenous interferon and/or ribavirin. Here, we discuss the discovery, development, pharmacologic characterization, and results from the phase 3 trials of sofosbuvir. Hepatitis C is a chronic disease, for which most patients have been undiagnosed, are unwilling to start treatment, or are ineligible for treatment because of the high toxicity and low efficacy of interferon and ribavirin-based therapy. Clinical studies with sofosbuvir have demonstrated significant improvement over the prior standard of care, thus ushering in a new paradigm of HCV treatment and an update of treatment guidelines.

Keywords: Ledipasvir; Sofosbuvir; Direct acting antivirals.

Abbreviations: AASLD, American Association for the Study of Liver Diseases; BCRP, breast cancer resistance protein; BMI, body mass index; CYP, cytochrome p450 genes; DAAs, direct acting antivirals; DNA, deoxyribonucleic acid; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; FDA, Food and Drug Administration; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IAS-USA, International Antiviral Society-USA; IDSA, Infectious Diseases Society of America; IU, international unit; NS, nonstructural; PegIFN, pegylated interferon; OAT1, organic anion-transporting protein 1; OCT2, organic cation transporter 2; P-gp, p-glycoprotein; PI, protease inhibitors; QTc, corrected QT; RAV, resistance-associated variant; RBV, ribavirin; RNA, ribonucleic acid; SVR, sustained virologic response; STR, single-tablet-regimen.

Received: 21 December 2014; Revised: 18 January 2015; Accepted: 19 January 2015

© 2015 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Ltd. All rights reserved.

Introduction

In the last 3 years, hepatitis C virus (HCV) treatment has undergone significant changes. Direct acting antivirals (DAAs), when combined with pegylated interferon (PegIFN) and ribavirin (RBV), improved rates of cure in chronic HCV infection as compared to treatment with PegIFN and RBV alone.1 Protease inhibitors (PIs) were the first class of DAAs to be approved for treatment of HCV and target the nonstructural protein (NS3)/4A serine protease, which processes the nascent viral poly-protein, allowing for HCV replication.1 The first NS3/4A protease inhibitors approved for use in the U.S., telaprevir and boceprevir, each required coadministration with PegIFN and RBV and the use of complex response-guided therapy algorithms to demonstrate improved sustained virologic response (SVR) rates compared with PegIFN and RBV alone for treatment of HCV genotype 1.1 Although this therapeutic approach represented an advancement in the treatment of HCV, it resulted in increased toxicity and increased potential for significant drug-to-drug interactions.2

The continued search to improve upon the clinical profile of DAAs led to the evaluation of other key viral targets, including structural and nonstructural proteins.3 To date, lead antiviral compounds have been generated against two additional targets. These include the NS5A replication scaffold, also known as the membranous web, and the NS5B ribonucleic acid (RNA)-dependent RNA polymerase (Fig. 1).

The nonstructural protein NS5B, an RNA dependent RNA polymerase, is an attractive target for the development of HCV therapies as nucleoside and nucleotide polymerase inhibitors have been a mainstay of antiviral therapy for a number of chronic viral diseases. In the HCV lifecycle, replication requires NS5B to copy the RNA genome and to transcribe messenger RNA.2-4 These essential steps in the lifecycle of HCV are critical for viral replication, and thus inhibition of NS5B prevents viral propagation.4

Compounds that inhibit NS5B are classified into two subclasses: nucleos(t)ide inhibitors and non-nucleoside inhibitors.4 Nucleos(t)ide inhibitors are analogues of the naturally occurring polymerase substrates and cause premature chain termination when incorporated into the nascent nucleic acid chain.1,4 Since the HCV NS5B polymerase’s active site is highly conserved across genotypes, nucleos(t)-tide inhibitors tend to have similar antiviral activity across all HCV genotypes, referred to as pan-genotypic activity. Many also have a high genetic barrier to the development of drug...
resistance. In contrast, non-nucleoside polymerase inhibitors bind distal to the catalytic site, are less likely to have pan-genotypic activity, and have thus far demonstrated a lower genetic barrier to resistance.

In the quest for an inhibitory NS5B drug prototype, nearly 100 crystal structures of the HCV NS5B were studied. Visually, the NS5B has a “right hand configuration”, with the readily recognized finger, palm, and thumb domains common to many polymerases. Researchers at Pharmasset Inc. investigated compounds of the nucleoside class that could inhibit HCV replication in multiple HCV genotypes. Their goal was to identify agents with improved potency and enhanced pharmacokinetic properties, thereby allowing for once-daily dosing at low doses that could achieve high concentrations of the active triphosphate in the liver.

Discovery and development

The goal during development of sofosbuvir was to create a prodrug compound with optimal oral absorption and potent antiviral activity. Following absorption, liver enzymes hydrolyze the terminal carboxylic acid ester of the phosphoramidite moiety, and a cascade of chemical and enzymatic events produce the pharmacologically active uridine triphosphate analogue. The triphosphate of 2'-alpha-F-2'-beta-C-methyl uridine is a potent inhibitor of the NS5B polymerase and exhibits a long intracellular half-life of 36 h. Initially the antiviral potency of a mixture of PSI-7977 diastereomers was evaluated, but it was later discovered that a purified non-racemic single diastereomer produced significantly greater reductions in HCV RNA. The discovery and characterization of this single diastereomer resulted in the first crystallization and X-ray derived structure of a nucleotide phosphoramidate, a DAA with improved potency and enhanced pharmacokinetic properties. This compound, PSI-7977, is now known as sofosbuvir and allows for once-daily dosing and the potential for generating high concentrations of the active triphosphate in the liver. Gilead Sciences acquired Pharmasset Inc. and PSI-7977 in November of 2011 and conducted additional preclinical and clinical research to evaluate the pharmacology and clinical safety and efficacy (Phase 2b and 3) of sofosbuvir, the results of which are summarized here. On December 6, 2013 the Food and Drug Administration (FDA) approved Sovaldi™ (sofosbuvir) 400 mg tablets for use in combination with other agents for the treatment of chronic HCV infection in adults.

Pharmacology

Absorption, metabolism, and elimination

Sofosbuvir is a prodrug administered once-daily as a 400 mg oral tablet without a food or fasting requirement. Sofosbuvir is absorbed with a peak plasma concentration observed at ~0.5–2 h post-dose. Following absorption, sofosbuvir is metabolized in hepatocytes, where it is converted to the active nucleoside triphosphate form, GS-461203. This requires two phosphorylation events that are mediated by endogenous host cell kinases. GS-461203 has a long half-life of approximately 18 h, supportive of once daily dosing. GS-461203 is irreversibly metabolized to the inactive phosphate free metabolite of the nucleotide, GS-331007. This metabolite is largely eliminated by passive filtration in the renal glomerulus. Prodrug not taken up by cells is also converted to GS-331007 (Fig. 2). GS-331007 from intracellular and extracellular metabolism accounts for greater than 90% of the systemically circulating drug-related material, while the parent sofosbuvir molecule accounts for approximately 4% of circulating drug related material and has a relatively short half-life of 0.5–0.8 h. Mass balance study of sofosbuvir elucidated that 76% of the drug was eliminated in the urine primarily as the GS331007 metabolite, 14% in feces, and 3% in expelled air. While GS-331007 is eliminated through the kidneys both by passive and active filtration/transport, it is not a substrate for the renal transporters (organic anion-transporting peptide 1 (OAT1), organic cation transporter 2 (OCT2), MATE1, p-glycoprotein (P-gp), and breast cancer resistance protein (BCRP)) in vitro.

Drug-to-drug interactions

Sofosbuvir is a substrate of the drug transporters P-gp and BCRP, while GS-331007 is not. As such, sofosbuvir should not be administered with potent inducers of intestinal P-gp, such as rifampin and Saint John’s wort, which may result in reduced absorption.

Fig. 1. Overview of direct-acting antivirals (DAAs). DAAs, direct acting antivirals.
Additionally, co-administration of sofosbuvir with select anticonvulsants, rifabutin, rifapentine, or tipranavir/ritonavir, is not recommended.\textsuperscript{11} The cytochrome p450 genes (CYP3A) encode a number of monoxygenase enzymes that are used to metabolize many drugs. Since sofosbuvir is not metabolized by, nor does it inhibit or induce CYP3A, it does not have many of the drug-to-drug interactions involved with other HCV antivirals.\textsuperscript{11} Sofosbuvir has been evaluated and found to have no clinically significant drug interactions with many of the common medications metabolized by CYP3A enzymes, including tacrolimus, cyclosporine, and methadone.\textsuperscript{11}

It is estimated that up to 30\% of human immunodeficiency virus (HIV) positive patients are infected with HCV, and thus drug-to-drug interactions with HIV antiretrovirals can be problematic in HCV treatment. The fixed-dose combination emtricitabine/tenofovir disoproxil fumarate, the single-tablet regimen of emtricitabine/ritonavir/tenofovir disoproxyl fumarate and efavirenz/emtricitabine/tenofovir disoproxyl fumarate, ritonavir-boosted HIV protease inhibitors darunavir and Atazanavir, and raltegravir are among the commonly used antiretrovirals evaluated in drug interaction studies. These combination were found to have no clinically significant interaction with sofosbuvir.\textsuperscript{11}

**Evaluation in hepatic and renal impairment**

Availability of safe treatment options for those with advanced fibrosis and cirrhosis, as well as those with diminished renal function, is a significant medical need for patients with HCV. The pharmacokinetics, safety, and antiviral activity of sofosbuvir were evaluated in HCV-infected subjects with moderate or severe hepatic impairment.\textsuperscript{15} Sofosbuvir was well tolerated during the 7 day dosing period.\textsuperscript{13} Systemic exposure to sofosbuvir was approximately two-fold higher in cirrhotic subjects relative to HCV-infected non-cirrhotic subjects, but there was no change in exposure to GS-331007.\textsuperscript{15} Additionally, HCV RNA was significantly decreased in subjects with Child Pugh Class B and C, where respective median day

<table>
<thead>
<tr>
<th>Table 1. Impact of intestinal P-gp inducers on sofosbuvir (SOF)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Concomitant drug class</strong></td>
</tr>
<tr>
<td>Anticonvulsants:</td>
</tr>
<tr>
<td>Carbamazepine</td>
</tr>
<tr>
<td>Phenytoin</td>
</tr>
<tr>
<td>Phenytoin</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
</tr>
<tr>
<td>Antiimycobacterials:</td>
</tr>
<tr>
<td>Rifabutin</td>
</tr>
<tr>
<td>Rifapentine</td>
</tr>
<tr>
<td>Rifampin</td>
</tr>
<tr>
<td>Antiretrovirals:</td>
</tr>
<tr>
<td>Tipranavir/ritonavir</td>
</tr>
<tr>
<td>Herbal Supplements:</td>
</tr>
<tr>
<td>St. John’s Wort</td>
</tr>
</tbody>
</table>

seven change from baseline in HCV RNA was $-3.65$ and $-3.14$ log$_{10}$ international unit (IU)/mL, respectively. These observed declines were less profound than in subjects without cirrhosis.\textsuperscript{15} Based on these data, no dose adjustment of sofosbuvir is warranted in mild, moderate, or severe hepatic impairment, although viral suppression may be slower among subjects with Child-Pugh Class B and C.

As in patients with advanced hepatic disease, patients with renal failure present challenges to the treatment of HCV with historically approved regimens. The pharmacokinetics of sofosbuvir and GS-331007 were evaluated in HCV-negative subjects with normal renal function and mild, moderate, or severe renal impairment.\textsuperscript{16} Subjects with mild, moderate, and severe renal impairment had approximately 56\%, 90\%, and 456\% higher GS-331007 AUC, respectively, than subjects with normal renal function.\textsuperscript{16} The pharmacokinetics of sofosbuvir and GS-331007 were also evaluated in subjects with end stage renal disease (ESRD), dosed predialysis and postdialysis.\textsuperscript{16} In subjects with ESRD, dialysis is essential to eliminate GS-331007 from the body.\textsuperscript{16} Based on these evaluations, no dose adjustment of sofosbuvir is warranted in mild or moderate renal impairment, when estimated glomerular filtration rate (eGFR) is $\geq 30$ mL/min/1.73 m$^2$. The safety and efficacy of sofosbuvir has not been established in patients with severe renal impairment (eGFR $< 30$ mL/min) and ESRD, including patients requiring hemodialysis, and therefore, no dose recommendation can be made at this time. Studies are currently underway to determine dosing and effectiveness of sofosbuvir in these patients.

**Toxicology studies**

Nucleos(t)ide analogues that have high affinity for mitochondrial polymerases can cause mitochondrial damage, and ultimately, cell death. This may result in many of the toxicities that have been seen with other members of this antiviral class. Sofosbuvir was found in vitro to have a low affinity for host cellular and mitochondrial deoxyribonucleic acid (DNA) and RNA polymerases, contributing to a low overall toxicity profile and differentiating sofosbuvir from other nucleos(t)ide analogue antivirals (Table 2).\textsuperscript{13} The effect of sofosbuvir 400 and 1200 mg on corrected QT (QTc) interval was also evaluated in a rat challenge, single-dose, placebo-, and active-controlled (moxifloxacin 400 mg) thorough QT study in 59 healthy subjects.\textsuperscript{17} The maximum change in
Sofosbuvir administered up to three times the maximum recommended dose (1200 mg) did not have a clinically meaningful effect on QTcF intervals. Clinical trials

Sofosbuvir is indicated in the U.S. for treatment of chronic HCV genotypes 1 through 4 in treatment-naïve and experienced patients, with or without HIV co-infection when used in combination with other antiviral agents. These indications were granted by the U.S. FDA after a review of data from phase 2 and 3 clinical trials. These trials evaluated the safety and efficacy of 12 to 24 weeks of sofosbuvir in combination with RBV, with and without PegIFN for treatment of genotypes 1 through 4. The recommended regimen and treatment duration for sofosbuvir combination therapy in HCV mono-infected and HCV/HIV-1 co-infected patients are summarized in Table 3.

Phase 3 studies in genotypes 1, 4, 5 and 6

The phase 3 study, NEUTRINO, evaluated 327 treatment-naïve subjects infected with chronic HCV genotypes 1, 4, 5, and 6, including 54 patients (17%) with compensated cirrhosis. Subjects were treated with 12 weeks of sofosbuvir 400 mg once daily, weight-based dosed RBV, 1200 mg >75 kg and 1000 mg ≤75 kg (RibaspHERE®) divided in two doses, and pegIFN once weekly (Pegasys®). Ninety-nine percent of subjects achieved HCV RNA below the limit of quantification (≤25 IU/mL) by week four and end of treatment, and 90% achieved SVR12. On-treatment viral kinetics did not predict SVR, thus, response-guided therapy is not indicated with sofosbuvir-based therapy. Subjects with genotype 1 achieved 90% SVR12, while 96% of genotype 4 and 100% of genotypes 5 and 6 subjects achieved SVR. Subjects with cirrhosis, the majority of whom were infected with genotype 1, had an overall SVR12 rate of 80%. High rates of SVR12 were seen across all genotypes and in patients with factors that have historically predicted negative outcomes (high body mass index (BMI), black race, IL-28B non-CC genotype, and high HCV viral load).

No subject experienced on-treatment virologic breakthrough, and relapse accounted for all virologic failures. Deep virologic sequencing analysis of samples from subjects who relapsed did not identify the sofosbuvir resistance-associated variant (RAV), S282T. The combination of sofosbuvir, RBV, and PegIFN was safe and well tolerated, with fewer than 2% of subjects discontinuing therapy. The most commonly reported adverse events were fatigue, headache, insomnia, and nausea. These side effects are typically associated with RBV and/or PegIFN. The addition of sofosbuvir to this combination did not increase the severity of reported adverse events.

Based on results observed in NEUTRINO, the U.S. FDA modeled an SVR rate in HCV genotype 1 patients who had failed prior PegIFN-based therapy. The FDA model predicted that the response rate of treatment-experienced patients treated with 12 weeks of sofosbuvir, PegIFN, and RBV would approximate the observed response rate in NEUTRINO subjects with multiple baseline factors traditionally associated with a lower response to interferon-based treatment. These factors include genotype 1 HCV, Metavir F3/F4 stages of fibrosis, nonCC should be hyphenated: non-CC IL-28B haplotype, and HCV RNA >800,000 IU/mL. The SVR12 rate in NEUTRINO among the subset of 52 subjects with all four of these characteristics was 71% (37/52). The safety and efficacy of 24 weeks of the interferon-free regimen of sofosbuvir plus RBV for treatment of genotype 1 HCV was evaluated in a phase 2 single-center, two part, randomized controlled trial conducted at the Clinical Research Center of the National Institutes of Health. The SPARE study enrolled 60 subjects, whose baseline characteristics reflected a traditionally difficult to cure population, including black race (83%), BMI >30 kg/m² (48%), non-CC IL-28B haplotype (81%), genotype 1a (70%), advanced liver disease (23%), and baseline HCV RNA levels >800,000 IU/mL (62%). Overall, 68% of genotype 1 subjects treated with sofosbuvir and weight-based dose of RBV achieved SVR.

Phase 3 studies in genotypes 2 and 3

The phase three clinical trials evaluating genotypes 2 and 3 included FISSION, POSTRON, FUSION, and VALENCE. These trials evaluated the safety and efficacy of different durations of therapy using all oral regimens of sofosbuvir and weight-based RBV in genotypes 2 and 3 HCV infection.

The FISSION trial randomized 499 subjects, including 100 patients with cirrhosis, to receive either sofosbuvir (400 mg once daily) and weight-based RBV for 12 weeks or to receive PegIFN alfa-2a and RBV (800 mg daily divided in two doses) for 24 weeks. The primary endpoint was SVR12, with a prespecified noninferiority margin of 15%. Baseline demographics were well balanced between the study arms. The majority of subjects in both arms were Caucasian, which is representative of the demographics of patients infected with genotypes 2 and 3. The majority of the subjects in this study were infected with HCV genotype 3, comprising 73% of the subjects enrolled. Overall, 67% of subjects in the PegIFN + RBV arm and 67% of the subjects in the sofosbuvir + RBV arm achieved SVR12; therefore, the study met its primary endpoint of noninferiority. SVR occurred in 97% of the HCV genotype 2 subjects and in 56% of HCV genotype 3 subjects treated with time-matched and baseline-adjusted QTcF intervals following a single dose of sofosbuvir (400 and 1200 mg) and moxifloxacin (400 mg; positive control) were 2.36, 2.57, and 11.3, respectively. Sofosbuvir administered up to three times the maximum recommended dose (1200 mg) did not have a clinically meaningful effect on QTcF intervals.

### Table 2. Inhibition of host polymerase

<table>
<thead>
<tr>
<th></th>
<th>IC50 μM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DNA Pol α</td>
</tr>
<tr>
<td>SOF Triphosphate</td>
<td>&gt;200</td>
</tr>
<tr>
<td>Controls</td>
<td>aphidicolin</td>
</tr>
<tr>
<td>IC50</td>
<td>(7.3)</td>
</tr>
</tbody>
</table>

The triphosphate of sofosbuvir (SOF) did not inhibit human DNA or RNA polymerases.
sofosbuvir and RBV. In comparison, the response rates were 78% and 63% in subjects treated with PegIFN and RBV, respectively.\textsuperscript{18} SVR rates for genotype 2 and 3 subjects who received PegIFN and RBV were 62% and 30%, respectively.\textsuperscript{18} The difference in response rates with sofosbuvir and RBV vs. PegIFN and RBV was statistically significant (\(p<0.001\)) among genotype 2 infected subjects.\textsuperscript{18} Overall virologic relapse occurred among 30% of subjects in the sofosbuvir and RBV arm and among 22% of subjects in the PegIFN and RBV arm.\textsuperscript{18} No S282T RAVs were identified upon deep sequencing of virus samples from subjects who did not achieve SVR.\textsuperscript{18} Sofosbuvir combined with RBV was well tolerated, and discontinuation of treatment occurred rarely at 1%, compared to 11% in the PegIFN and RBV arm.\textsuperscript{18} None of the discontinuations due to adverse events in the sofosbuvir-containing arm was deemed related to sofosbuvir.\textsuperscript{18}

POSITRON was a randomized, double-blinded, placebo-controlled trial that evaluated the safety and efficacy of 12 weeks of treatment with sofosbuvir and weight-based RBV in 207 subjects compared to 71 subjects who received placebo.\textsuperscript{20} Subjects enrolled in this trial were intolerant to, ineligible for, or unwilling to receive interferon-based therapy. Sixteen percent of subjects had evidence of cirrhosis at baseline.\textsuperscript{20} Both study arms were balanced with respect to subject demographics and baseline characteristics, including 51% genotype 2 and 49% genotype 3.\textsuperscript{20} None of the subjects who received placebo achieved SVR, while 93% of genotype 2 and 61% of genotype 3 subjects who received active treatment achieved SVR (\(p<0.001\)).\textsuperscript{20} Robust response was seen in both HCV Genotypes 2 and 3 subjects without cirrhosis, with 81% achieving SVR (92% of subjects with HCV genotype 2 and 68% of those with HCV genotype 3).\textsuperscript{20} Cirrhosis did not negatively impact outcomes among genotype 2 subjects, 94% of whom achieved SVR.\textsuperscript{20} However, genotype 3 subjects with cirrhosis had a blunted response with an SVR rate of 21%.\textsuperscript{20} Failures to achieve SVR were due to relapse, and no S282T RAVs were identified upon deep sequencing of samples from subjects who did not achieve SVR.\textsuperscript{20} Treatment with sofosbuvir was well tolerated, with reported adverse events being those most commonly associated with RBV, such as fatigue, headache, nausea, insomnia, and rash.\textsuperscript{20} Study discontinuation due to adverse events was minimal at 2% in the sofosbuvir arm and 4% in the placebo arm.\textsuperscript{20}

FUSION was a randomized, double-blinded trial that evaluated the safety and efficacy of either 12 or 16 weeks of treatment with sofosbuvir and weight-based RBV in 201 subjects who did not achieve SVR with prior interferon-based treatment (relapers and nonresponders).\textsuperscript{20} Baseline subject demographics and disease characteristics were balanced between the 12 and 16 week arms.\textsuperscript{20} Sixty-three percent of subjects were infected with genotype 3 HCV, and 34% of the overall population had evidence of cirrhosis at baseline.\textsuperscript{20} The 12 week duration of therapy resulted in 50% of subjects achieving an SVR12, compared to 71% with 16 weeks of therapy.\textsuperscript{20} A substantial increase in SVR rate was seen in genotype 3 subjects who received 16 weeks of therapy.\textsuperscript{20} The SVR12 results in genotype 3 subjects treated for 12 weeks was 30% compared to 62% in subjects who received 16 weeks of treatment.\textsuperscript{20} All virologic failures were due to relapse, and no S282T RAVs were identified upon deep sequencing.\textsuperscript{20} Treatment discontinuations were infrequent, occurring at 1% in the 12 week arm compared to 0% in the 16 week study arm.\textsuperscript{20} Sofosbuvir-based therapy was well tolerated, with the most common adverse events being those attributed to RBV.\textsuperscript{20} No additional safety signals were identified, and adverse events were not increased with the additional 4 weeks of therapy.\textsuperscript{20}

Results of these trials demonstrated that 12 weeks of sofosbuvir plus RBV was optimal for genotype 2 patients, whereas genotype 3 patients would benefit from extending treatment duration.\textsuperscript{20} The VALENCE trial was conducted to confirm the treatment duration for genotype 2 infected patients and to explore the efficacy of extending treatment duration to 24 weeks for genotype 3 infected patients.\textsuperscript{21} The VALENCE trial evaluated the efficacy and safety of sofosbuvir and weight-based RBV in 419 HCV treatment-naive and experienced genotype 2 and 3 infected subjects.\textsuperscript{21} HCV genotype 2 subjects received 12 weeks of therapy, while genotype 3 subjects were treated for 24 weeks.\textsuperscript{21} SVR12 was achieved in 93% of HCV genotype 2 subjects and in 84% of subjects with genotype 3.\textsuperscript{21} The extension of therapy to 24 weeks in genotype 3 subjects substantially improved SVR rates, which defined the recommended duration of therapy of 24 weeks for genotype 3 infection.\textsuperscript{21} Failures to achieve SVR were due to relapse, and no S282T RAVs were identified upon deep sequencing.\textsuperscript{21} The extension of therapy to 24 weeks in genotype 3 subjects did not demonstrate a significant increase in adverse events or discontinuations.\textsuperscript{21}

The sofosbuvir pivotal trials across all genotypes demonstrated SVR12 rates greater than 90% in treatment-naive subjects (Fig. 3).

**Clinical trials in HCV/HIV co-infection**

PHOTON-1 evaluated the safety and efficacy of 12 or 24 weeks of an interferon-free all-oral regimen of sofosbuvir 400 mg daily and weight-based RBV dosed twice daily in

---

**Table 3. Recommended sofosbuvir combination regimen and treatment duration**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with genotype 1 or 4</td>
<td>Sofosbuvir 400 mg once daily, RBV 1000/1200 in two divided dose,(^a) and PegIFN once weekly(^b)</td>
</tr>
<tr>
<td>IFN-ineligible patients with genotype 1</td>
<td>Sofosbuvir 400 mg once daily and RBV 1000/1200 in two divided dose</td>
</tr>
<tr>
<td>Patients with genotype 2</td>
<td>Sofosbuvir 400 mg once daily and RBV 1000/1200 in two divided dose</td>
</tr>
<tr>
<td>Patients with genotype 3</td>
<td>Sofosbuvir 400 mg once daily and RBV 1000/1200 in two divided dose</td>
</tr>
</tbody>
</table>

\(^a\)Dose of ribavirin is weight-based (<75 kg = 1000 mg and \(\geq 75 \text{ kg} = 1200 \text{ mg}\)).

\(^b\)Dose of PegIFN alfa is per the prescribing information.

---

---
This study enrolled 223 HCV/HIV co-infected subjects, including treatment-naive genotype 1 and both treatment-naive and experienced genotype 2 and 3 subjects. Subjects infected with genotype 1 were treated for 24 weeks, treatment-naive genotype 2 and 3 subjects were treated for 12 weeks, and treatment-experienced genotype 2 and 3 subjects were treated for 24 weeks duration. In the study, greater than 90% of subjects were receiving concomitant antiretroviral medications for the treatment of HIV-1. Treatment-naïve genotype 1, 2, and 3 subjects achieved SVR12 rates of 76%, 88%, and 67%, respectively (Fig. 4). Ninety-two percent and 94% of treatment-experienced genotype 2 and 3 subjects achieved SVR12, respectively. One HCV genotype 1 subject and one HCV genotype 2 subject experienced virologic breakthrough in this study. Notably, both subjects were found to have undetectable plasma drug concentrations, consistent with nonadherence. Relapse accounted for all other subjects that did not achieve SVR, and no S282T RAVs were identified by deep sequencing. Sofosbuvir and RBV were safe and well tolerated with fewer than 4% of subjects discontinuing therapy due to an adverse event. The most common adverse events were fatigue, headache, insomnia, and nausea, consistent with those that have been associated with RBV in previous studies. Additionally, HCV treatment with sofosbuvir and RBV had no impact on CD4 percentage or HIV viral load. Sofosbuvir was also evaluated in an additional HCV/HIV co-infection study that was conducted at a single site in Puerto Rico. This study evaluated the safety and efficacy of 12 weeks of sofosbuvir combined with PegIFN and RBV for treatment-naïve, genotypes 1–4 HCV/HIV co-infected subjects without cirrhosis. Twenty-one of twenty-three subjects (91%) achieved SVR12. Efficacy and safety data from both of these studies in HCV mono-infected subjects is summarized in Table 4.

Efficacy and safety data from both of these studies in HCV/HIV coinfection and previously reported results in HCV mono-infected subjects (Fig. 4). Furthermore, given the high rates of response observed in the PHOTON-1 study, the labeling includes an indication for the use of sofosbuvir and RBV for 24 weeks in HCV genotype 1 patients who are interferon ineligible.

The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), in collaboration with the International Antiviral Society-USA (IAS-USA), announced the launch of a new website, HCVguidelines.org in January 2014. In contrast with traditional treatment guidelines published in Hepatology, this web-based guidance will be revised regularly with new therapeutic options as they receive FDA approval.

### Sofosbuvir-based all-oral DAA therapy

The overarching goal of research in the HCV arena has been to develop highly efficacious, oral, and safe DAAs or combinations of DAAs that can be used without interferon, and possibly, without RBV. Sofosbuvir has been studied in combination with ledipasvir, an NSSA inhibitor, as a single-tablet regimen (STR) in phase 3 clinical trials for patients with HCV genotype 1 infection. Additionally, phase 2 trials have examined safety and efficacy of this STR in other genotypes. STRs are a mainstay of HIV treatment and demonstrate increased adherence and reduced resistance as compared to multitablet regimens. On October 10, 2014 the FDA approved Harvoni® (ledipasvir/sofosbuvir), the first once daily STR for treatment of chronic HCV in genotype 1 infected patients, including patients with compensated cirrhosis. The recommended treatment duration for ledipasvir/sofosbuvir STR in patients with chronic HCV genotype 1 infection is summarized in Table 4.

The safety and efficacy of once-daily ledipasvir/sofosbuvir was evaluated in three phase 3 studies, conducted in 1,952 HCV genotype-1 infected subjects. The study population included 308 (16%) black patients, 224 (16%) compensated cirrhotics, 591 (26%) patients with BMI ≥ 30 kg/m², and 1,597 (82%) with high HCV RNA (>800,000 IU/mL). ION-1 is an open-label phase 3 study that evaluated the safety and efficacy of ledipasvir/sofosbuvir in 865 HCV genotype 1 subjects with and without cirrhosis. Subjects were randomized 1:1:1:1 to receive 12 or 24 weeks of ledipasvir/sofosbuvir with or without weight-based dose RBV. High rates of SVR12 (98–99%) were achieved across all arms, indicating that a 12 week duration of ledipasvir/sofosbuvir STR was as efficacious as a 24 week duration and that RBV did not increase SVR (Fig. 5). Given the high rates of SVR observed in phase 2 studies among genotype 1

---

Fig. 3. SVR 12 across treatment-naïve genotypes 1, 2, 3, 4, 5, 6.
subjects without cirrhosis treated with ledipasvir/sofosbuvir for 8 and 12 weeks with or without RBV, the feasibility of shortening treatment duration was evaluated in the phase 3 randomized, open-label ION-3 study. This study compared the safety and efficacy of 8 weeks of the ledipasvir/sofosbuvir STR with and without RBV to a 12 week course of the STR in 647 genotype 1 treatment-naive subjects without cirrhosis. SVR12 ranged from 93–96% across all arms, establishing the noninferiority of the 8-week duration of therapy with the ledipasvir/sofosbuvir STR without RBV to the other treatment arms (Fig. 5). In a posthoc analysis of SVR12, having 6 million IU/mL of HCV RNA or greater at baseline was associated with higher relapse in the 8 week arms of the study. To evaluate the safety and efficacy of this STR in treatment-experienced genotype 1 patients, ION-2 randomized 440 subjects, with and without cirrhosis, to receive 12 versus 24 weeks of ledipasvir/sofosbuvir with and without weight-based RBV. Two hundred and thirty-one (53%) of subjects had previously failed to respond to treatment with an HCV NS3/4A protease-inhibitor combined with PegIFN and RBV. SVR12 was achieved by 94–99% of subjects across all arms, and addition of RBV did not increase SVR (Fig. 5). The most common adverse events in the ION studies were fatigue, headache, nausea, and insomnia. These adverse events, in addition to laboratory abnormalities, occurred more frequently in the RBV-containing arms of the studies.

Conclusions

The last 5 years have seen significant advances in the treatment of chronic HCV with improvements in efficacy as well as safety and tolerability. Sofosbuvir, a nucleotide analogue, represents a first in class antiviral with unique safety and efficacy properties. These include convenient dosing, limited drug-to-drug interactions, high efficacy, a high barrier to genetic resistance, and high rates of SVR when used with other currently approved HCV antiviral agents. In clinical trials, sofosbuvir plus RBV, with or without PegIFN, has demonstrated SVR rates in excess of 80% for most cirrhotic patients and greater than or equal to 90% in the majority of treatment naive patients. Based on these data, the AASLD/IDSA guidance recommended sofosbuvir for the treatment of HCV patients. The combination of ledipasvir/sofosbuvir as a STR has been evaluated in large phase 3 clinical trials and demonstrated minimal toxicities and high efficacy, with an overall SVR of 97% in genotype 1 infected patients, without the need for either interferon or RBV. With recent FDA approval of ledipasvir/sofosbuvir, the majority of patients with chronic genotype 1 HCV may achieve SVR in as short as 8 or 12 weeks of treatment with a once daily STR. Studies are underway to evaluate whether the duration of therapy may be further reduced by increasing the number of DAAs with different mechanisms of action in HCV regimens.

Acknowledgements

Copy editing and organizational advice was provided by the following people at Gilead Sciences, Foster City, California: Nika Burger, Diana Brainard, Betty Chiang, Bill Geyer, Bruce Kreter, Chris Lahart, Jamie Zagorski, Brent Peterson, and Anita Mathias; concept was developed by: George Wu of the university of connecticut.

Table 4. Recommended treatment duration for once daily administered ledipasvir/sofosbuvir in patients with chronic HCV genotype 1

<table>
<thead>
<tr>
<th>Patient population</th>
<th>Recommended treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment-naive with or without cirrhosis</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Treatment-naive patients without cirrhosis who have pretreatment HCV RNA less than 6 million IU/mL</td>
<td>Consider 8 weeks</td>
</tr>
<tr>
<td>Treatment-experienced* without cirrhosis</td>
<td>12 weeks</td>
</tr>
<tr>
<td>Treatment-experienced* with cirrhosis</td>
<td>24 weeks</td>
</tr>
</tbody>
</table>

*Treatment-experienced patients who have failed treatment with either PegIFN + ribavirin or an HCV protease inhibitor + PegIFN + ribavirin.
Fig. 5. ION phase 3 program (ION-1, ION-2, ION-3) efficacy summary. Error bars represent 95% confidence intervals.

Conflict of interest
None

Author contributions
Manuscript writing (TM, CS, SS).

References


[17] Compropst M. PSI-7977 Has no effect on QTcF intervals at Therapeutic or Supratherapeutic Doses. 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). 2011; San Francisco, CA, USA.


McQuaid T. et al: Sofosbuvir in HCV treatment
